Company prepares new product launches starting in 2025.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

German family-owned drug major Boehringer Ingelheim and Cue Biopharma (Nasdaq: CUE) have announced a strategic research ...

Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company ... Please be aware that information relating to the approval status and labels of approved products of Boehringer may vary ...

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune ...

Boehringer Ingelheim has launched a new range of cat and dog supplements under the Seraquin brand. The three supplements ...

The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. Boehringer Ingelheim International: Leading the Way in ...

Hubertus von Baumbach joined Boehringer Ingelheim in 2001. He held various leadership positions in Finance & Controlling, until he was appointed to the Board of Managing Directors in 2009 ...

Ingelheim, Germany ... aware that information relating to the approval status and labels of approved products of Boehringer may vary from country to country, and a country-specific press release ...